Drugs / ZT002 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07020884 | Aug 2024 → May 2025 | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZT002 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07020884 ↗ |
| Route | Subcutaneous | “Dose 1 administered subcutaneously (SC), Q2W” NCT07020884 ↗ |